Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADDXF Addex Therapeutics	$0.99	$0.99	$0.99 ▼ $0.99	N/A	0.25	N/A	N/A
AKTX Akari Therapeutics	$1.18 +2.2%	$1.27	$0.85 ▼ $4.40	$37.65M	0.21	31,403 shs	2,252 shs
ALIM Alimera Sciences	$5.54	$5.55	$2.61 ▼ $5.65	$290.24M	1.25	376,318 shs	N/A
MBRX Moleculin Biotech	$0.35 +0.7%	$0.75	$0.25 ▼ $4.71	$4.80M	1.38	1.93 million shs	1.26 million shs
RGRX RegeneRx Biopharmaceuticals	$0.00	$0.00	$0.00 ▼ $0.07	N/A	2.98	21 shs	1 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADDXF Addex Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
AKTX Akari Therapeutics	0.00%	+1.80%	-12.59%	+8.26%	-62.91%
ALIM Alimera Sciences	0.00%	0.00%	0.00%	0.00%	+0.36%
MBRX Moleculin Biotech	0.00%	+12.11%	-48.03%	-57.32%	-90.36%
RGRX RegeneRx Biopharmaceuticals	0.00%	0.00%	0.00%	-85.71%	-85.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	1.5428 of 5 stars	0.0	5.0	0.0	0.0	1.8	3.3	0.0
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	3.1504 of 5 stars	3.5	2.0	0.0	0.0	3.4	1.7	1.3
RGRX RegeneRx Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADDXF Addex Therapeutics	0.00	N/A	N/A	N/A
AKTX Akari Therapeutics	0.00	N/A	N/A	N/A
ALIM Alimera Sciences	0.00	N/A	N/A	N/A
MBRX Moleculin Biotech	3.00	Buy	$4.00	1,042.86% Upside
RGRX RegeneRx Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALIM, ADDXF, MBRX, RGRX, and AKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.84 per share	N/A
ALIM Alimera Sciences	$99.68M	2.91	N/A	N/A	$0.88 per share	6.30
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
RGRX RegeneRx Biopharmaceuticals	$80K	0.00	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADDXF Addex Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-213.59%	-65.60%	8/18/2025 (Estimated)
ALIM Alimera Sciences	-$20.13M	-$1.57	N/A	26.38	N/A	-14.74%	-33.70%	-9.63%	N/A
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-278.80%	-100.11%	8/4/2025 (Estimated)
RGRX RegeneRx Biopharmaceuticals	-$1.73M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ALIM, ADDXF, MBRX, RGRX, and AKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
RGRX RegeneRx Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADDXF Addex Therapeutics	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	0.16	0.16
ALIM Alimera Sciences	1.80	2.79	2.62
MBRX Moleculin Biotech	N/A	1.35	1.35
RGRX RegeneRx Biopharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADDXF Addex Therapeutics	N/A
AKTX Akari Therapeutics	5.06%
ALIM Alimera Sciences	99.83%
MBRX Moleculin Biotech	15.52%
RGRX RegeneRx Biopharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADDXF Addex Therapeutics	N/A
AKTX Akari Therapeutics	38.10%
ALIM Alimera Sciences	31.40%
MBRX Moleculin Biotech	1.90%
RGRX RegeneRx Biopharmaceuticals	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADDXF Addex Therapeutics	26	N/A	N/A	Not Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
ALIM Alimera Sciences	150	52.39 million	35.94 million	Optionable
MBRX Moleculin Biotech	20	14.13 million	13.86 million	Not Optionable
RGRX RegeneRx Biopharmaceuticals	3	1.51 million	1.32 million	Not Optionable

ALIM, ADDXF, MBRX, RGRX, and AKTX Headlines

Recent News About These Companies

EIGRQ Eiger BioPharmaceuticals, Inc.

July 19, 2024 | seekingalpha.com

The Hawryluk Biopharmaceutical Scholars

January 1, 2024 | kellogg.northwestern.eduK

Regenerx Biopharmaceuticals Inc RGRXD

November 5, 2023 | morningstar.comM

Regenerx Biopharm In (RGRXD)

October 30, 2023 | investing.com

LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China

September 21, 2023 | businesswire.com

Jeannette company becomes leader in recycling biopharmaceutical waste

September 18, 2023 | triblive.comT

RGRX RegeneRx Biopharmaceuticals, Inc.

August 26, 2023 | seekingalpha.com

RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations

August 15, 2023 | finance.yahoo.com

RegeneRx Receives Stockholder Approval for Reverse Stock Split

August 8, 2023 | finance.yahoo.com

RegeneRx To Extend Consent Solicitation Vote

August 1, 2023 | finance.yahoo.com

Bristol-Myers to Split Off Mead Johnson

July 6, 2023 | thestreet.com

PlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage Initiation

May 19, 2023 | thestreet.com

First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

April 13, 2023 | finance.yahoo.com

Biopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030

April 7, 2023 | marketwatch.com

Biopharmaceutical Third Party Logistics (3PL) Market | 2023-2029

April 7, 2023 | marketwatch.com

CURIA, CORNING BOOST BIOPHARMACEUTICAL CONTINUOUS-FLOW DEVELOPMENT, MANUFACTURING

April 4, 2023 | bernama.comB

2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029

March 1, 2023 | marketwatch.com

Biopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028

February 25, 2023 | marketwatch.com

Biopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027

February 24, 2023 | marketwatch.com

Biopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

February 12, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM, ADDXF, MBRX, RGRX, and AKTX Company Descriptions

Addex Therapeutics OTCMKTS:ADDXF

$0.99 0.00 (0.00%)

As of 02/3/2023

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Akari Therapeutics NASDAQ:AKTX

$1.18 +0.03 (+2.16%)

As of 07/3/2025 01:00 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Moleculin Biotech NASDAQ:MBRX

$0.35 +0.00 (+0.72%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$0.35 0.00 (0.00%)

As of 07/3/2025 04:43 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

RegeneRx Biopharmaceuticals OTCMKTS:RGRX

$0.0002 0.00 (0.00%)

As of 07/3/2025

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time